Aigen Investment Management LP Takes Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Aigen Investment Management LP bought a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLDGet Rating) during the first quarter, HoldingsChannel reports. The firm bought 12,095 shares of the biopharmaceutical company’s stock, valued at approximately $115,000.

Other hedge funds have also recently modified their holdings of the company. First Horizon Advisors Inc. boosted its holdings in shares of Amicus Therapeutics by 155.7% during the 4th quarter. First Horizon Advisors Inc. now owns 2,917 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 1,776 shares in the last quarter. Advisor Group Holdings Inc. boosted its holdings in shares of Amicus Therapeutics by 30.4% during the 4th quarter. Advisor Group Holdings Inc. now owns 9,516 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 2,217 shares in the last quarter. Sage Capital Advisors llc bought a new stake in shares of Amicus Therapeutics during the 1st quarter valued at $103,000. Guerra Pan Advisors LLC purchased a new position in shares of Amicus Therapeutics in the 4th quarter worth about $175,000. Finally, Calton & Associates Inc. purchased a new position in shares of Amicus Therapeutics in the 1st quarter worth about $165,000.

Insiders Place Their Bets

In other Amicus Therapeutics news, CEO John F. Crowley sold 11,346 shares of the business’s stock in a transaction dated Friday, June 3rd. The stock was sold at an average price of $8.00, for a total value of $90,768.00. Following the completion of the transaction, the chief executive officer now owns 932,807 shares of the company’s stock, valued at approximately $7,462,456. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Amicus Therapeutics news, CEO John F. Crowley sold 11,346 shares of the business’s stock in a transaction dated Friday, June 3rd. The stock was sold at an average price of $8.00, for a total value of $90,768.00. Following the completion of the transaction, the chief executive officer now owns 932,807 shares of the company’s stock, valued at approximately $7,462,456. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Ellen Rosenberg sold 11,122 shares of the business’s stock in a transaction dated Tuesday, June 21st. The stock was sold at an average price of $10.00, for a total value of $111,220.00. Following the completion of the transaction, the insider now directly owns 291,830 shares of the company’s stock, valued at approximately $2,918,300. The disclosure for this sale can be found here. In the last 90 days, insiders sold 130,779 shares of company stock valued at $1,237,966. 2.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group assumed coverage on Amicus Therapeutics in a research report on Wednesday, April 13th. They issued a “neutral” rating for the company. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $15.25.

Amicus Therapeutics Price Performance

FOLD opened at $12.18 on Friday. The stock has a 50-day moving average price of $9.95 and a 200-day moving average price of $9.02. The company has a debt-to-equity ratio of 1.63, a current ratio of 4.00 and a quick ratio of 3.81. The firm has a market cap of $3.41 billion, a PE ratio of -12.56 and a beta of 0.96. Amicus Therapeutics, Inc. has a 1 year low of $5.91 and a 1 year high of $12.69.

Amicus Therapeutics (NASDAQ:FOLDGet Rating) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.02. Amicus Therapeutics had a negative return on equity of 95.05% and a negative net margin of 84.97%. During the same period last year, the business posted ($0.19) earnings per share. Sell-side analysts predict that Amicus Therapeutics, Inc. will post -0.88 earnings per share for the current fiscal year.

Amicus Therapeutics Company Profile

(Get Rating)

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.

Featured Stories

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLDGet Rating).

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.